The clinical efficacy and pathological assessment of neoadjuvant imatinib treatment in patients with primary gastrointestinal stromal tumors

Pre-neoadjuvant tumor size, tumor location, mitotic count, and post-operative imatinib treatment were identified as prognostic factors for GIST patients who received NAT. Pathological regression was associated with radiological changes in the tumor, but it was not correlated with long-term patient prognosis.